Subject(s)
Anesthesiology , Humans , Anniversaries and Special Events , Critical Care , Societies, MedicalSubject(s)
Humans , Male , Female , Anesthesiology/trends , Cardiopulmonary Resuscitation , Anniversaries and Special Events , Anesthesia/methods , SpainABSTRACT
We present an update of the 2020 Recommendations on neuromuscular blockade of the SEDAR. The previous ones dated 2009. A modified Delphi consensus analysis (experts, working group, and previous extensive bibliographic revision) 10 recommendations were produced1: neuromuscular blocking agents were recommended for endotracheal intubation and to avoid faringo-laryngeal and tracheal lesions, including critical care patients.2 We recommend not to use neuromuscular blocking agents for routine insertion of supraglotic airway devices, and to use it only in cases of airway obstruction or endotracheal intubation through the device.3 We recommend to use a rapid action neuromuscular blocking agent with an hypnotic in rapid sequence induction of anesthesia.4 We recommend profound neuromuscular block in laparoscopic surgery.5 We recommend quantitative monitoring of neuromuscular blockade during the whole surgical procedure, provided neuromuscular blocking agents have been used.6 We recommend quantitative monitoring through ulnar nerve stimulation and response evaluation of the adductor pollicis brevis, acceleromyography being the clinical standard.7 We recommend a recovery of neuromuscular block of at least TOFr ≥ 0.9 to avoid postoperative residual neuromuscular blockade.8 We recommend drug reversal of neuromuscular block at the end of general anesthetic, before extubation, provided a TOFr ≥ 0.9 has not been reached.9 We recommend to choose anticholinesterases for neuromuscular block reversal only if TOF≥2 and a TOFr ≥ 0.9 has not been attained.10 We recommend to choose sugammadex instead of anticholinesterases for reversal of neuromuscular blockade induced with rocuronium.
Subject(s)
Anesthetics , Neuromuscular Blockade , Neuromuscular Blocking Agents , Neuromuscular Nondepolarizing Agents , Humans , Neuromuscular Blockade/adverse effects , Neuromuscular Blockade/methods , Cholinesterase Inhibitors/adverse effects , Anesthesia, GeneralABSTRACT
Se presenta la actualización 2020 de las Recomendaciones de bloqueo neuromuscular de la Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor (SEDAR). Las anteriores databan de 2009. Tras un análisis de consenso Delphi (expertos, grupo de trabajo y revisión bibliográfica previa) se generaron 10 recomendaciones: 1) Se recomienda el uso de fármacos bloqueantes neuromusculares (fbnm) para facilitar la intubación traqueal y evitar lesiones faringo-laringo-traqueales en cualquier paciente, incluidos pacientes críticos. 2) Se recomienda no utilizar fbnm para la inserción rutinaria de dispositivos supraglóticos y utilizar solo en caso de obstrucción de la vía aérea o intubación traqueal a través de este. 3) Se recomienda utilizar un fármaco bloqueante neuromuscular de inicio de acción rápido asociado al agente hipnótico en la inducción de secuencia rápida. 4) Se recomienda utilizar un nivel de bloqueo neuromuscular profundo en cirugía laparoscópica. 5) Se recomienda el uso de monitorización cuantitativa del bloqueo neuromuscular durante todo el procedimiento quirúrgico, siempre que se utilicen fbnm. 6) Se recomienda la monitorización cuantitativa mediante estimulación del nervio cubital y evaluación de la respuesta en el músculo aductor corto del pulgar, siendo el estándar clínico la aceleromiografía (AMG). 7) Se recomienda una recuperación del bloqueo neuromuscular al menos hasta alcanzar un TOFr ≥ 0,9 para evitar el bloqueo neuromuscular residual postoperatorio. 8) Se recomienda la reversión farmacológica del bloqueo neuromuscular al finalizar la anestesia general, previo a la extubación traqueal siempre que no se haya alcanzado un TOFr ≥ 0,9. 9) Se recomienda utilizar fármacos anticolinesterásicos para la reversión del bloqueo neuromuscular solo cuando el tren de cuatro estímulos (TOF) es ≥ 2 y no se haya alcanzado un TOFr ≥ 0,9. 10)...(AU)
We present an update of the 2020 Recommendations on neuromuscular blockade of the SEDAR. The previous ones dated 2009. A modified Delphi consensus analyisis (experts, working group, and previous extensive bibliographic revision) 10 recommendations were produced: (1) neuromuscular blocking agents were recommended for endotracheal intubation and to avoid faringo-laryngeal and tracheal lesions, including critical care patients. (2) We recommend not to use neuromuscular blocking agents for routine insertion of supraglotic airway devices, and to use it only in cases of airway obstruction or endotracheal intubation through the device. (3) SWe recommend to use a rapid action neuromuscular blocking agent with an hypnotic in rapid sequence induction of anesthesia. (4) We recommed profound neuromuscular block in laparoscopic surgery. (5) We recommend quantitative monitoring Sof neuromuscular blockade during the whole surgical procedure, provided neuromuscular blocking agents have been used. (6) We recommend quantitative monitoring through ulnar nerve stimulation and response evaluation of the adductor pollicis brevis, acceleromyography being the clinical standard. (7) We recommned a recovery of neuromuscular block of at least TOFr ≥ 0.9 to avoid postoperative residual neuromuscular blockade. (8) We recommend drug reversal of neuromuscular block at the end of general anesthetic, before extubation, provided a TOFr ≥ 0.9 has not been reached. (9) We recommend to choose anticholinesterases for neuromuscular block reversal only if TOF ≥ 2 and a TOFr ≥ 0.9 has not been atained. (10) We recommend to choose sugammadex instead of anticholinesterases for reversal of neuromuscular blockade induced with rocuronium.(AU)
Subject(s)
Humans , eHealth Strategies , Neuromuscular Blockade , Perioperative Period , Muscle Relaxants, Central , Neuromuscular Blocking Agents , Anesthesiology , SpainABSTRACT
INTRODUCTION: Neuromuscular blockade enables airway management, ventilation and surgical procedures. However there is no national consensus on its routine clinical use. The objective was to establish the degree of agreement among anaesthesiologists and general surgeons on the clinical use of neuromuscular blockade in order to make recommendations to improve its use during surgical procedures. METHODS: Multidisciplinary consensus study in Spain. Anaesthesiologists experts in neuromuscular blockade management (n=65) and general surgeons (n=36) were included. Delphi methodology was selected. A survey with 17 final questions developed by a dedicated scientific committee was designed. The experts answered the successive questions in two waves. The survey included questions on: type of surgery, type of patient, benefits/harm during and after surgery, impact of objective neuromuscular monitoring and use of reversal drugs, viability of a multidisciplinary and efficient approach to the whole surgical procedure, focussing on the level of neuromuscular blockade. RESULTS: Five recommendations were agreed: 1) deep neuromuscular blockade is very appropriate for abdominal surgery (degree of agreement 94.1%), 2) and in obese patients (76.2%); 3) deep neuromuscular blockade maintenance until end of surgery might be beneficial in terms of clinical aspects, such as as immobility or better surgical access (86.1 to 72.3%); 4) quantitative monitoring and reversal drugs availability is recommended (89.1%); finally 5) anaesthesiologists/surgeons joint protocols are recommended. CONCLUSIONS: Collaboration among anaesthesiologists and surgeons has enabled some general recommendations to be established on deep neuromuscular blockade use during abdominal surgery.
Subject(s)
Neuromuscular Blockade/methods , Adult , Anesthesiology , Contraindications, Procedure , Delayed Emergence from Anesthesia/prevention & control , Delphi Technique , Expert Testimony , Female , General Surgery , Humans , Intraoperative Awareness/prevention & control , Male , Middle Aged , Neuromuscular Blockade/adverse effects , Neuromuscular Blockade/standards , Neuromuscular Blocking Agents/administration & dosage , Neuromuscular Blocking Agents/adverse effects , Neuromuscular Monitoring , Physicians/psychologyABSTRACT
Estudios recientes indican que la infusión intravenosa de clorhidrato de ketamina (antagonista de los receptores N-metil-D-aspartato) conlleva una rápida reducción de la sintomatología depresiva. Una mujer de 42 años, con cáncer de mama y depresión mayor resistente a tratamiento médico recibió una infusión intravenosa de 0,3mg/kg de ketamina en 90min durante 5 días consecutivos. Se apreció una disminución significativa de la sintomatología evaluada mediante la escala de depresión de Hamilton de 22 a 13 (-41%) con un efecto mantenido a los 14 días. Se discute el posible mecanismo terapéutico(AU)
Recent studies indicate that the intravenous infusion of ketamine hydrochloride (an N-methyl-D-aspartate receptor antagonist) leads to a rapid reduction in depressive symptoms. A 42 year-old woman with breast cancer and major depression resistant to medical treatment received a 90 minute intravenous infusion of 0.3mg/kg ketamine for 5 consecutive days. A significant reduction from 22 to 13 (-41%) was observed in the symptoms assessed using the Hamilton scale, with the effect maintained for 14 days. The possible therapeutic mechanism is discussed(AU)
Subject(s)
Humans , Female , Adult , Ketamine/pharmacokinetics , Ketamine/therapeutic use , Depressive Disorder, Major/complications , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/drug therapy , Postoperative Period , Postoperative Care/methods , Antidepressive Agents/metabolism , Antidepressive Agents/pharmacokinetics , Antidepressive Agents/therapeutic use , Psychotherapy/methods , Psychotherapy/trendsABSTRACT
Recent studies indicate that the intravenous infusion of ketamine hydrochloride (an N-methyl-D-aspartate receptor antagonist) leads to a rapid reduction in depressive symptoms. A 42 year-old woman with breast cancer and major depression resistant to medical treatment received a 90 minute intravenous infusion of 0.3 mg/kg ketamine for 5 consecutive days. A significant reduction from 22 to 13 (-41%) was observed in the symptoms assessed using the Hamilton scale, with the effect maintained for 14 days. The possible therapeutic mechanism is discussed.
Subject(s)
Depressive Disorder/drug therapy , Excitatory Amino Acid Antagonists/administration & dosage , Ketamine/administration & dosage , Neuralgia/drug therapy , Pain, Postoperative/drug therapy , Pilonidal Sinus/surgery , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Adenocarcinoma/secondary , Adenocarcinoma/therapy , Analgesics/therapeutic use , Antidepressive Agents/pharmacokinetics , Antidepressive Agents/therapeutic use , Antineoplastic Agents, Hormonal/therapeutic use , Bone Neoplasms/secondary , Bone Neoplasms/therapy , Breast Neoplasms/complications , Breast Neoplasms/drug therapy , Breast Neoplasms/surgery , Combined Modality Therapy , Depressive Disorder/complications , Drug Interactions , Drug Resistance , Excitatory Amino Acid Antagonists/pharmacokinetics , Female , Humans , Ketamine/pharmacokinetics , Mastectomy , Middle Aged , Neuralgia/etiology , Neuralgia/psychologyABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Anesthesiology/education , Writing/standards , Periodicals as Topic/ethics , Periodicals as Topic , Periodicals as Topic/standards , Periodicals as Topic/trendsSubject(s)
Takotsubo Cardiomyopathy , gamma-Cyclodextrins/therapeutic use , Female , Humans , Middle Aged , SugammadexABSTRACT
No disponible
